XVIVO — Xvivo Perfusion AB Share News
0.000.00%
- SEK6.49bn
- SEK6.30bn
- SEK812.17m
Brief: Xvivo Perfusion Q3 EBITDA Raises To SEK 5.2 Million
Brief: Xvivo Perfusion Q2 Net Sales Up At SEK 46.1 Mln
Brief: Xvivo Perfusion: Perfadex Plus Approved By The FDA
Brief: Xvivo Perfusion changes the date of reporting of interim report January - June 2018 to July 20, 2018
Brief: United Therapeutics And Xvivo Perfusion Announce Collaboration
Brief: Xvivo Perfusion: Positive Findings In PrimECC Study
Brief: XVIVO Perfusion Has Submitted Premarket Approval Application For XPS With STEEN Solution To FDA
Brief: Xvivo Perfusion Q1 Adjusted. EBITDA Sek 7.2 Million
Brief: Xvivo Perfusion AB Net Sales Of Non-Durable Goods In Q4 Amounted To Sek 39.4 (34.6) Million
Brief: Xvivo Perfusion Q3 EBITDA ex-items down at SEK 4.4 mln
Brief: Xvivo Perfusion Q2 EBITDA ex-items down at SEK 6.2 mln
Brief: Xvivo Perfusion Q1 EBITDA decreases to SEK 5.0 mln
Brief: Xvivo Perfusion: subscription price per new share in private placement at SEK 76.50
Brief: XVIVO Perfusion plans private placement
Brief: Xvivo Perfusion Q4 adjusted EBITDA drops to SEK 6.7 mln
Brief: Xvivo Perfusion Q3 EBITDA ex-items effecting comparability up by 22 pct
Brief: Xvivo signs a contract in Spain
Brief: Xvivo Perfusion Q2 EBITDA ex-items up at SEK 6.9 million
Brief: Xvivo Perfusion: share warrant program fully subscribed